Anti-PEG product references

Discover more about our polyethylene glycol (PEG) products through publications.

The following list a partial list of papers published and customer testimonials using our anti-PEG​ RabMAb® products. 

Anti-Polyethylene glycol antibody [PEG-B-47] (ab51257)

Toxicol Pathol ​41:970-83 (2013).
Rudmann DG  et al.
High Molecular Weight Polyethylene Glycol Cellular Distribution and PEG-associated Cytoplasmic Vacuolation Is Molecular Weight Dependent and Does Not Require Conjugation to Proteins. 

​Mol Cancer Ther​ 12:1816-28 (2013). 
Hendriks BS  et al.
ERBB2 expression level on HER2-targeted liposomal doxorubicin-mediated drug delivery: multiple low-affinity interactions lead to a threshold effect. 

ACS Nano 6:8007-14 (2012).
Bitner BR  et al.
Antioxidant carbon particles improve cerebrovascular dysfunction following traumatic brain injury. 

Bioconjug Chem 23:485-99 (2012). ​​​
Sherman MR  et al.
Role of the methoxy group in immune responses to mPEG-protein conjugates. 

Bioconjug Chem 23:248-63 (2012). ​
Cong Y  et al.
Site-specific PEGylation at histidine tags. 

​Shock 31:192-200 (2009). ​​​
Sakai H  et al.
Fluid resuscitation with artificial oxygen carriers in hemorrhaged rats: profiles of hemoglobin-vesicle degradation and hematopoiesis for 14 days. 

Mol Immunol. 2014 Feb;57(2):236-46
Saifer MG et al.
Selectivity of binding of PEGs and PEG-like oligomers to anti-PEG antibodies induced by methoxyPEG-proteins. 

J Control Release. 2013 Feb 10;165(3):183-90
Shiraishi K et al.
Hydrophobic blocks of PEG-conjugates play a significant role in the accelerated blood clearance (ABC) phenomenon.

Bioconjug Chem. 2012 May 16;23(5):881-99.
Cheng TL et al.
Analytical measurement of PEGylated molecules.​

​Int J Nanomedicine. 2012;7:2557-71.
Oberoi HS et al.
Cisplatin-loaded core cross-linked micelles: comparative pharmacokinetics, antitumor activity, and toxicity in mice.​

Soft Matter. 2014 Feb 14;10(6):831-9.
Schulz M et al.​
Lateral surface engineering of hybrid lipid-BCP vesicles and selective nanoparticle embedding.​​

J Control Release. 2013 Nov 10;171(3):339-48. 
Desale SS et al. 
Biodegradable hybrid polymer micelles for combination drug therapy in ovarian cancer.​

​BioDrugs. 2014 Aug;28(4):393-402.​
Pink A et al.
Purification, Characterization and Plasma Half-Life of PEGylated Soluble Recombinant Non-HA-Binding CD44.​

J Immunol. 2013 Nov 1;191(9):4599-610. 
Suchard SJ et al. 
A monovalent anti-human CD28 domain antibody antagonist: preclinical efficacy and safety.

Anal Bioanal Chem. 2012 Jan;402(3):1229-39.
Wang SJ et al.
Attribution of the discrepancy between ELISA and LC-MS/MS assay results of a PEGylated scaffold protein in post-dose monkey plasma samples due to the presence of anti-drug antibodies.

Bioconjug Chem. 2010 Jul 21;21(7):1264-70. 
Su YC et al.
Sensitive quantification of PEGylated compounds by second-generation anti-poly(ethylene glycol) monoclonal antibodies.

Integr Biol (Camb). 2014 Jul 21;6(8):766-80. 
Myers DE et al. 
CD19-antigen specific nanoscale liposomal formulation of a SYK P-site inhibitor causes apoptotic destruction of human B-precursor leukemia cells.

Mol Pharm. 2012 May 7;9(5):1291-301.
Elliott VL et al.
Evidence for metabolic cleavage of a PEGylated protein in vivo using multiple analytical methodologies.

​​For more product references, please visit ​ab51257 product reference page.

Polyethylene Glycol (PEG) RabMAb ELISA Kit  (ab138914)

J Interferon Cytokine Res 33:769-77 (2013). 
Lee JI  et al.
Site-specific PEGylation enhances the pharmacokinetic properties and antitumor activity of interferon beta-1b. 

Anal Chem 85:9630-7 (2013). ​​​
Liu Q  et al.
Method for characterization of PEGylated bioproducts in biological matrixes. 

Korean J Gastroenterol 58:107-10 (2011).
Tae HJ  et al.
[A case of pegylated interferon alpha-2a monotherapy in a peritoneal dialysis patient with chronic hepatitis C]. 

Invest Ophthalmol Vis Sci 52:1392-403 (2011). ​
Peng S  et al. 
Claudin-19 and the barrier properties of the human retinal pigment epithelium. 

Invest Ophthalmol Vis Sci 51:3216-25 (2010). 
Peng S  et al.
Minimal effects of VEGF and anti-VEGF drugs on the permeability or selectivity of RPE tight junctions.

For more product references, please visit ab138914 product reference page.

Customer Testimonial

"The relatively high (low nM) affinity of the (PEG RabMAb primary antibody, ab53449)  meant that we could extensively wash the wells of the assay (with PBS no Tween) and not remove the specifically bound Ab – this essentially meant we had a ‘sensitive’ assay with ‘low background levels’ and a ‘good signal-to-noise window."

Provided by an Abreview​ - 

Sign up